Vanguard Personalized Indexing Management LLC raised its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 11.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,390 shares of the biopharmaceutical company’s stock after acquiring an additional 655 shares during […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seventeen ratings firms that are currently covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year […]
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.23, Briefing.com reports. The firm had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. During the same […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) was the recipient of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 2,500,000 shares, a drop of 10.7% from the March 31st total of 2,800,000 shares. Based on an average daily volume of 836,100 shares, […]
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.75) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link. Alnylam […]